

Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (Text with EEA relevance)

CHAPTER I

GENERAL PROVISIONS

- Article 1 Scope
- Article 2 Definitions
- Article 3 General principle

CHAPTER II

AUTHORISATION PROCEDURE FOR A CLINICAL TRIAL

- Article 4 Prior authorisation
- Article 5 Submission of an application
- Article 6 Assessment report — Aspects covered by Part I
- Article 7 Assessment report — Aspects covered by Part II
- Article 8 Decision on the clinical trial
- Article 9 Persons assessing the application
- Article 10 Specific considerations for vulnerable populations
- Article 11 Submission and assessment of applications limited to aspects covered by Part I or Part II of the assessment report
- Article 12 Withdrawal
- Article 13 Resubmission
- Article 14 Subsequent addition of a Member State concerned

CHAPTER III

AUTHORISATION PROCEDURE FOR A SUBSTANTIAL MODIFICATION OF A CLINICAL TRIAL

- Article 15 General principles
- Article 16 Submission of application
- Article 17 Validation of an application for the authorisation of a substantial modification of an aspect covered by Part I of the assessment report
- Article 18 Assessment of a substantial modification of an aspect covered by Part I of the assessment report
- Article 19 Decision on the substantial modification of an aspect covered by Part I of the assessment report
- Article 20 Validation, assessment and decision regarding a substantial modification of an aspect covered by Part II of the assessment report
- Article 21 Substantial modification of aspects covered by Parts I and II of the assessment report

Status: Point in time view as at 31/01/2020.

Changes to legislation: There are currently no known outstanding effects for the Regulation (EU) No 536/2014 of the European Parliament and of the Council. (See end of Document for details)

- Article 22 Assessment of a substantial modification of aspects covered by Parts I and II of the assessment report — Assessment of the aspects covered by Part II of the assessment report
- Article 23 Decision on the substantial modification of aspects covered by Parts I and II of the assessment report
- Article 24 Persons assessing the application for a substantial modification

CHAPTER IV

APPLICATION DOSSIER

- Article 25 Data submitted in the application dossier
- Article 26 Language requirements
- Article 27 Update by way of delegated acts

CHAPTER V

PROTECTION OF SUBJECTS AND INFORMED CONSENT

- Article 28 General rules
- Article 29 Informed consent
- Article 30 Informed consent in cluster trials
- Article 31 Clinical trials on incapacitated subjects
- Article 32 Clinical trials on minors
- Article 33 Clinical trials on pregnant or breastfeeding women
- Article 34 Additional national measures
- Article 35 Clinical trials in emergency situations

CHAPTER VI

START, END, TEMPORARY HALT, AND EARLY TERMINATION OF A CLINICAL TRIAL

- Article 36 Notification of the start of a clinical trial and of the end of the recruitment of subjects
- Article 37 End of a clinical trial, temporary halt and early termination of a clinical trial and submission of the results
- Article 38 Temporary halt or early termination by the sponsor for reasons of subject safety
- Article 39 Update of the contents of the summary of results and summary for laypersons

CHAPTER VII

SAFETY REPORTING IN THE CONTEXT OF A CLINICAL TRIAL

- Article 40 Electronic database for safety reporting
- Article 41 Reporting of adverse events and serious adverse events by the investigator to the sponsor
- Article 42 Reporting of suspected unexpected serious adverse reactions by the sponsor to the Agency
- Article 43 Annual reporting by the sponsor to the Agency
- Article 44 Assessment by Member States

Status: Point in time view as at 31/01/2020.

Changes to legislation: There are currently no known outstanding effects for the Regulation (EU) No 536/2014 of the European Parliament and of the Council. (See end of Document for details)

- Article 45 Technical aspects
- Article 46 Reporting with regard to auxiliary medicinal products

CHAPTER VIII

CONDUCT OF A CLINICAL TRIAL, SUPERVISION BY THE SPONSOR, TRAINING AND EXPERIENCE, AUXILIARY MEDICINAL PRODUCTS

- Article 47 Compliance with the protocol and good clinical practice
- Article 48 Monitoring
- Article 49 Suitability of individuals involved in conducting the clinical trial
- Article 50 Suitability of clinical trial sites
- Article 51 Traceability, storage, return and destruction of investigational medicinal products
- Article 52 Reporting of serious breaches
- Article 53 Other reporting obligations relevant for subject safety
- Article 54 Urgent safety measures
- Article 55 Investigator's brochure
- Article 56 Recording, processing, handling and storage of information
- Article 57 Clinical trial master file
- Article 58 Archiving of the clinical trial master file
- Article 59 Auxiliary medicinal products

CHAPTER IX

MANUFACTURING AND IMPORT OF INVESTIGATIONAL MEDICINAL PRODUCTS AND AUXILIARY MEDICINAL PRODUCTS

- Article 60 Scope of this Chapter
- Article 61 Authorisation of manufacturing and import
- Article 62 Responsibilities of the qualified person
- Article 63 Manufacturing and import
- Article 64 Modification of authorised investigational medicinal products
- Article 65 Manufacturing of auxiliary medicinal products

CHAPTER X

LABELLING

- Article 66 Unauthorised investigational and unauthorised auxiliary medicinal products
- Article 67 Authorised investigational and authorised auxiliary medicinal products
- Article 68 Radiopharmaceuticals used as investigational medicinal products or as auxiliary medicinal products for a medical diagnosis
- Article 69 Language
- Article 70 Delegated act

CHAPTER XI

SPONSOR AND INVESTIGATOR

- Article 71 Sponsor

Status: Point in time view as at 31/01/2020.

Changes to legislation: There are currently no known outstanding effects for the Regulation (EU) No 536/2014 of the European Parliament and of the Council. (See end of Document for details)

Article 72	Co-sponsorship
Article 73	Principal investigator
Article 74	Legal representative of the sponsor in the Union
Article 75	Liability

CHAPTER XII

DAMAGE COMPENSATION

Article 76	Damage compensation
------------	---------------------

CHAPTER XIII

SUPERVISION BY MEMBER STATES, UNION INSPECTIONS AND CONTROLS

Article 77	Corrective measures to be taken by Member States
Article 78	Member State inspections
Article 79	Union controls

CHAPTER XIV

IT INFRASTRUCTURE

Article 80	EU portal
Article 81	EU database
Article 82	Functionality of the EU portal and the EU database

CHAPTER XV

COOPERATION BETWEEN MEMBER STATES

Article 83	National contact points
Article 84	Support by the Agency and the Commission
Article 85	Clinical Trials Coordination and Advisory Group

CHAPTER XVI

FEES

Article 86	General principle
Article 87	One payment per activity per Member State

CHAPTER XVII

IMPLEMENTING ACTS AND DELEGATED ACTS

Article 88	Committee procedure
Article 89	Exercise of the delegation

Status: Point in time view as at 31/01/2020.

Changes to legislation: There are currently no known outstanding effects for the Regulation (EU) No 536/2014 of the European Parliament and of the Council. (See end of Document for details)

CHAPTER XVIII

MISCELLANEOUS PROVISIONS

- Article 90 Specific requirements for special groups of medicinal products
- Article 91 Relation with other Union legislation
- Article 92 Investigational medicinal products, other products and procedures, free of charge for the subject
- Article 93 Data protection
- Article 94 Penalties
- Article 95 Civil and criminal liability

CHAPTER XIX

FINAL PROVISIONS

- Article 96 Repeal
- Article 97 Review
- Article 98 Transitional provision
- Article 99 Entry into force
Signature

ANNEX I

APPLICATION DOSSIER FOR THE INITIAL APPLICATION

- A. INTRODUCTION AND GENERAL PRINCIPLES
 - 1. The sponsor shall, where appropriate, refer to any previous applications...
 - 2. Where a clinical trial has more than one sponsor, detailed...
 - 3. The application shall be signed by the sponsor or a...
 - 4. The application dossier for an application limited to Part I...
 - 5. Without prejudice to Article 26, the application dossier for an...
- B. COVER LETTER
 - 6. The cover letter shall specify the EU trial number and...
 - 7. However, in the cover letter it is not necessary to...
 - 8. The cover letter shall indicate where the information listed in...
 - 9. The cover letter shall indicate if the clinical trial is...
 - 10. The cover letter shall indicate if the methodology of the...
 - 11. The cover letter shall indicate the location in the application...
 - 12. In the case of a resubmission, the cover letter shall...
- C. EU APPLICATION FORM
 - 13. The EU application form, duly completed.
- D. PROTOCOL
 - 14. The protocol shall describe the objective, design, methodology, statistical considerations,...
 - 15. The protocol shall be identified by:
 - 16. The protocol shall, when possible, be written in an easily...

Status: Point in time view as at 31/01/2020.

Changes to legislation: There are currently no known outstanding effects for the Regulation (EU) No 536/2014 of the European Parliament and of the Council. (See end of Document for details)

17. The protocol shall at least include:
 18. If a clinical trial is conducted with an active substance...
 19. With regard to the notification of adverse events, the protocol...
 20. The protocol shall describe the procedures for:
 21. In case the sponsor intends to submit a single safety...
 22. Issues regarding labelling and the unblinding of investigational medicinal products...
 23. The protocol shall be accompanied by the Charter of the...
 24. The protocol shall be accompanied by a synopsis of the...
- E. INVESTIGATOR'S BROCHURE (IB)
25. An IB, which has been prepared in accordance with the...
 26. The purpose of the IB is to provide the investigators...
 27. The information in the IB shall be presented in a...
 28. If the investigational medicinal product is authorised, and is used...
 29. For a multinational clinical trial where the medicinal product to...
 30. If the IB is not an SmPC, it shall contain...
- F. DOCUMENTATION RELATING TO COMPLIANCE WITH GOOD MANUFACTURING PRACTICE (GMP) FOR...
31. As regards documentation relating to GMP compliance, the following shall...
 32. No documentation needs to be submitted where the investigational medicinal...
 33. If the investigational medicinal product is not authorised, and does...
 34. In all other cases, a copy of the authorisation referred...
 35. For processes related to investigational medicinal products set out in...
- G. INVESTIGATIONAL MEDICINAL PRODUCT DOSSIER (IMPD)
36. The IMPD shall give information on the quality of any...
 - 1.1. Data relating to the investigational medicinal product
 - Introduction
 37. Regarding data, the IMPD may be replaced by other documentation...
 38. Each section of the IMPD shall be prefaced with a...
 39. The information in the IMPD shall be concise. The IMPD...
 - Quality data
 40. Quality data shall be submitted in a logical structure such...
 - Non-clinical pharmacology and toxicology data
 41. The IMPD shall also contain summaries of non-clinical pharmacology and...
 42. Non-clinical pharmacology and toxicology data shall be submitted in a...
 43. The IMPD shall provide a critical analysis of the data,...
 44. The IMPD shall contain a statement of the good laboratory...
 45. The test material used in toxicity studies shall be representative...
 - Data from previous clinical trials and human experience
 46. Data from previous clinical trials and human experience shall be...
 47. This section shall provide summaries of all available data from...
 - Overall risk and benefit assessment
 48. This section shall provide a brief integrated summary that critically...

Status: Point in time view as at 31/01/2020.

Changes to legislation: There are currently no known outstanding effects for the Regulation (EU) No 536/2014 of the European Parliament and of the Council. (See end of Document for details)

49. Where appropriate, safety margins shall be discussed in terms of...
- 1.2. Simplified IMPD by referring to other documentation
 50. The applicant may refer to other documentation submitted alone or...
Possibility of referring to the IB
 51. The applicant may either provide a stand-alone IMPD or cross-refer...
Possibility of referring to the SmPC
 52. The applicant may submit the version of the SmPC valid...
 53. If the investigational medicinal product is defined in the protocol...
- 1.3. IMPD in cases of placebo
 54. If the investigational medicinal product is a placebo, the information...
- H. AUXILIARY MEDICINAL PRODUCT DOSSIER
 55. Without prejudice to Article 65, the documentation requirements set out...
- I. SCIENTIFIC ADVICE AND PAEDIATRIC INVESTIGATION PLAN (PIP)
 56. If available, a copy of the summary of scientific advice...
 57. If the clinical trial is part of an agreed PIP,...
- J. CONTENT OF THE LABELLING OF THE INVESTIGATIONAL MEDICINAL PRODUCTS
 58. A description of the content of the labelling of the...
- K. RECRUITMENT ARRANGEMENTS (INFORMATION PER MEMBER STATE CONCERNED)
 59. Unless described in the protocol, a separate document shall describe...
 60. Where the recruitment of subjects is done through advertisement, copies...
- L. SUBJECT INFORMATION, INFORMED CONSENT FORM AND INFORMED CONSENT PROCEDURE (INFORMATION...)
 61. All information given to the subjects (or, where applicable, to...
 62. A description of procedures relating to informed consent for all...
 63. In the cases set out in paragraph 62, the information...
- M. SUITABILITY OF THE INVESTIGATOR (INFORMATION PER MEMBER STATE CONCERNED)
 64. A list of the planned clinical trial sites, the name...
 65. Description of the qualification of the investigators in a current...
 66. Any conditions, such as economic interests and institutional affiliations, that...
- N. SUITABILITY OF THE FACILITIES (INFORMATION PER MEMBER STATE CONCERNED)
 67. A duly justified written statement on the suitability of the...
- O. PROOF OF INSURANCE COVER OR INDEMNIFICATION (INFORMATION PER MEMBER STATE...)
 68. Proof of insurance, a guarantee, or a similar arrangement shall...
- P. FINANCIAL AND OTHER ARRANGEMENTS (INFORMATION PER MEMBER STATE CONCERNED)
 69. A brief description of the financing of the clinical trial....

Status: Point in time view as at 31/01/2020.

Changes to legislation: There are currently no known outstanding effects for the Regulation (EU) No 536/2014 of the European Parliament and of the Council. (See end of Document for details)

- 70. Information on financial transactions and compensation paid to subjects and...
- 71. Description of any other agreement between the sponsor and the...
- Q. PROOF OF PAYMENT OF FEE (INFORMATION PER MEMBER STATE CONCERNED)...
- 72. Proof of payment shall be submitted, if applicable.
- R. PROOF THAT DATA WILL BE PROCESSED IN COMPLIANCE WITH UNION...
- 73. A statement by the sponsor or his or her representative...

ANNEX II

APPLICATION DOSSIER FOR SUBSTANTIAL MODIFICATION

- A. INTRODUCTION AND GENERAL PRINCIPLES
 - 1. Where a substantial modification concerns more than one clinical trial...
 - 2. The application shall be signed by the sponsor or a...
- B. COVER LETTER
 - 3. A cover letter with the following information:
- C. MODIFICATION APPLICATION FORM
 - 4. The modification application form, duly completed.
- D. DESCRIPTION OF THE MODIFICATION
 - 5. The modification shall be presented and described as follows:
 - 6. The new version of the document shall be identified by...
- E. SUPPORTING INFORMATION
 - 7. Where applicable, additional supporting information shall at least include:
- F. UPDATE OF EU APPLICATION FORM
 - 8. If a substantial modification involves changes to entries on the...
- G. PROOF OF PAYMENT OF FEE (INFORMATION PER MEMBER STATE CONCERNED)...
- 9. Proof of payment shall be submitted, if applicable.

ANNEX III

SAFETY REPORTING

- 1. REPORTING OF SERIOUS ADVERSE EVENTS BY THE INVESTIGATOR TO THE...
 - 1. The investigator does not need to actively monitor subjects for...
- 2. REPORTING OF SUSPECTED UNEXPECTED SERIOUS ADVERSE REACTIONS (SUSARS) BY THE...
 - 2.1. Adverse Events and Causality
 - 2. Medication errors, pregnancies and uses outside what is foreseen in...
 - 3. In determining whether an adverse event is an adverse reaction,...
 - 4. In the absence of information on causality provided by the...

Status: Point in time view as at 31/01/2020.

Changes to legislation: *There are currently no known outstanding effects for the Regulation (EU) No 536/2014 of the European Parliament and of the Council. (See end of Document for details)*

- 2.2. Expectedness, unexpectedness and the RSI
 5. In determining whether an adverse event is unexpected, consideration shall...
 6. The expectedness of an adverse reaction shall be set out...
 7. The RSI shall be contained in the SmPC or the...
 8. The RSI may change during the conduct of a clinical...
 9. If information on expectedness has been provided by the reporting...
- 2.3. Information for the reporting of SUSARs
 10. The information shall at least include:
 11. In addition, in order to properly process the report electronically,...
- 2.4. Follow-up reports of SUSARs
 12. If the initial report of a SUSAR referred to in...
 13. The clock for initial reporting (day 0 = Di 0)...
 14. If significant new information on an already reported case is...
 15. If the initial report of a SUSAR referred to in...
 16. In cases where a SUSAR turns out to be fatal...
- 2.5. Unblinding treatment allocation
 17. The investigator shall only unblind the treatment allocation of a...
 18. When reporting a SUSAR to the Agency, the sponsor shall...
 19. If an event is potentially a SUSAR the blind shall...
 20. Unblinded information shall be accessible only to persons who need...
 21. However, for clinical trials carried out in high morbidity or...
 22. If following unblinding, an event turns out to be a...
3. ANNUAL SAFETY REPORTING BY THE SPONSOR
 23. The report shall contain, in an appendix, the RSI in...
 24. The RSI in effect at the start of the reporting...
 25. If there are significant changes to the RSI during the...

ANNEX IV

CONTENT OF THE SUMMARY OF THE RESULTS OF THE CLINICAL TRIAL

The summary of the results of the clinical trial shall...

- A. CLINICAL TRIAL INFORMATION:
- B. SUBJECT DISPOSITION:
- C. BASELINE CHARACTERISTICS:
- D. END POINTS:
- E. ADVERSE EVENTS:
- F. ADDITIONAL INFORMATION:

Status: Point in time view as at 31/01/2020.

Changes to legislation: There are currently no known outstanding effects for the Regulation (EU) No 536/2014 of the European Parliament and of the Council. (See end of Document for details)

ANNEX V

CONTENT OF THE SUMMARY OF THE RESULTS OF THE CLINICAL TRIAL FOR LAYPERSONS

The summary of the results of the clinical trial for...
Clinical trial identification (including title of the trial, protocol
number,...

ANNEX VI

LABELLING OF INVESTIGATIONAL MEDICINAL PRODUCTS AND AUXILIARY MEDICINAL PRODUCTS

- A. UNAUTHORISED INVESTIGATIONAL MEDICINAL PRODUCTS
 - A.1. General rules
 - 1. The following particulars shall appear on the immediate and the...
 - 2. Symbols or pictograms may be included to clarify certain information...
 - 3. The address and telephone number of the main contact shall...
 - A.2. Limited labelling of immediate packaging
 - A.2.1. Immediate and outer packaging provided together
 - 4. When the product is provided to the subject or the...
 - A.2.2. Small immediate packaging
 - 5. If the immediate packaging takes the form of blister packs...
- B. UNAUTHORISED AUXILIARY MEDICINAL PRODUCTS
 - 6. The following particulars shall appear on the immediate and the...
- C. ADDITIONAL LABELLING FOR AUTHORISED INVESTIGATIONAL MEDICINAL PRODUCTS
 - 7. In accordance with Article 67(2), the following particulars shall appear...
- D. REPLACING OF INFORMATION
 - 8. The particulars listed in sections A, B and C, other...
 - 9. The particulars referred to in the following points shall not...

ANNEX VII

CORRELATION TABLE

Status: Point in time view as at 31/01/2020.

Changes to legislation: There are currently no known outstanding effects for the Regulation (EU) No 536/2014 of the European Parliament and of the Council. (See end of Document for details)

- (1) [OJ C 44, 15.2.2013, p. 99.](#)
- (2) Position of the European Parliament of 3 April 2014 (not yet published in the Official Journal) and decision of the Council of 14 April 2014.
- (3) Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use ([OJ L 121, 1.5.2001, p. 34.](#))
- (4) Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products ([OJ L 18, 22.1.2000, p. 1.](#))
- (5) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use ([OJ L 311, 28.11.2001, p. 67.](#))
- (6) Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency ([OJ L 136, 30.4.2004, p. 1.](#))
- (7) Regulation (EU) No 182/2011 of the European Parliament and of the Council of 16 February 2011 laying down the rules and general principles concerning mechanisms for control by Member States of the Commission's exercise of implementing powers ([OJ L 55, 28.2.2011, p. 13.](#))
- (8) Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data ([OJ L 281, 23.11.1995, p. 31.](#))
- (9) Regulation (EC) No 45/2001 of the European Parliament and of the Council of 18 December 2000 on the protection of individuals with regard to the processing of personal data by the Community institutions and bodies and on the free movement of such data ([OJ L 8, 12.1.2001, p. 1.](#))
- (10) [OJ C 253, 3.9.2013, p. 10.](#)

Status:

Point in time view as at 31/01/2020.

Changes to legislation:

There are currently no known outstanding effects for the Regulation (EU) No 536/2014 of the European Parliament and of the Council.